Are women using postmenopausal estrogens? A community survey.
R B Harris,
A Laws,
V M Reddy,
A King and
W L Haskell
Stanford Center for Research in Disease Prevention, Stanford University, CA.
Self-reported estrogen and progestin use in a California communitywas determined in 1986-87 from a telephone survey of postmenopausalwomen (n = 954) ages 50-65 years. Current use of hormones wasreported by 32 percent; 26 percent took estrogens alone while6 percent used estrogen + progestin. Comparisons pointed tosignificant social network and medical care utilization differences.Women who used estrogen therapy were younger, thinner, livedin smaller household units, and were less likely to be widowed.
This article has been cited by other articles:
M. R. McClung, R. D. Wasnich, D. J. Hosking, C. Christiansen, P. Ravn, M. Wu, A. M. Mantz, J. Yates, P. D. Ross, A. C. Santora II, et al. Prevention of Postmenopausal Bone Loss: Six-Year Results from the Early Postmenopausal Intervention Cohort Study
J. Clin. Endocrinol. Metab.,
October 1, 2004;
89(10):
4879 - 4885.
[Abstract][Full Text][PDF]
X. L. Ma, F. Gao, J. Chen, T. A. Christopher, B. L. Lopez, E. H. Ohlstein, and T.-L. Yue Endothelial protective and antishock effects of a selective estrogen receptor modulator in rats
Am J Physiol Heart Circ Physiol,
February 1, 2001;
280(2):
H876 - H884.
[Abstract][Full Text][PDF]
X. L. Ma, F. Gao, C.-L. Yao, J. Chen, B. L. Lopez, T. A. Christopher, J. Disa, J.-L. Gu, E. H. Ohlstein, and T.-L. Yue Nitric Oxide Stimulatory and Endothelial Protective Effects of Idoxifene, a Selective Estrogen Receptor Modulator, in the Splanchnic Artery of the Ovariectomized Rat
J. Pharmacol. Exp. Ther.,
November 1, 2000;
295(2):
786 - 792.
[Abstract][Full Text]
G. A. Figtree, Y.-q. Lu, C. M. Webb, and P. Collins Raloxifene Acutely Relaxes Rabbit Coronary Arteries In Vitro by an Estrogen Receptor–Dependent and Nitric Oxide–Dependent Mechanism
Circulation,
September 7, 1999;
100(10):
1095 - 1101.
[Abstract][Full Text][PDF]
H. M. Perry III The Endocrinology of Aging
Clin. Chem.,
August 1, 1999;
45(8):
1369 - 1376.
[Abstract][Full Text][PDF]
N. L. Keating, P. D. Cleary, A. S. Rossi, A. M. Zaslavsky, and J. Z. Ayanian Use of Hormone Replacement Therapy by Postmenopausal Women in the United States
Ann Intern Med,
April 6, 1999;
130(7):
545 - 553.
[Abstract][Full Text][PDF]
E. Hemminki and K. McPherson Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials
BMJ,
July 19, 1997;
315(7101):
149 - 153.
[Abstract][Full Text]
S. E. McNagny and T. A. Jacobson Use of Postmenopausal Hormone Replacement Therapy by African American Women: The Importance of Physician Discussion
Arch Intern Med,
June 23, 1997;
157(12):
1337 - 1342.
[Abstract][PDF]
Y. Zhang, D. P. Kiel, B. E. Kreger, L. A. Cupples, R. C. Ellison, J. F. Dorgan, A. Schatzkin, D. Levy, and D. T. Felson Bone Mass and the Risk of Breast Cancer among Postmenopausal Women
N. Engl. J. Med.,
February 27, 1997;
336(9):
611 - 617.
[Abstract][Full Text][PDF]
J. L. Stanford and N. S. Weiss Hormone Replacement Therapy and Breast Cancer
Arch Fam Med,
June 1, 1996;
5(6):
349 - 350.
[Abstract][PDF]
A J Isaacs, A R Britton, and K. McPherson Utilisation of hormone replacement therapy by women doctors
BMJ,
November 25, 1995;
311(7017):
1399 - 1401.
[Abstract][Full Text]
J. L. Stanford, N. S. Weiss, L. F. Voigt, J. R. Daling, L. A. Habel, and M. A. Rossing Combined Estrogen and Progestin Hormone Replacement Therapy in Relation to Risk of Breast Cancer in Middle-aged Women
JAMA,
July 12, 1995;
274(2):
137 - 142.
[Abstract][PDF]